Literature DB >> 10896947

Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase.

D Chikazu1, Y Hakeda, N Ogata, K Nemoto, A Itabashi, T Takato, M Kumegawa, K Nakamura, H Kawaguchi.   

Abstract

We previously reported that fibroblast growth factor-2 (FGF-2) acts not only on osteoblasts to stimulate osteoclastic bone resorption indirectly but also on mature osteoclasts directly. In this study, we investigated the mechanism of this direct action of FGF-2 on mature osteoclasts using mouse and rabbit osteoclast culture systems. FGF-2 stimulated pit formation resorbed by isolated rabbit osteoclasts moderately from low concentrations (>/=10(-12) m), whereas at high concentrations (>/=10(-9) m) it showed stimulation on pit formation resorbed by unfractionated bone cells very potently. FGF-2 (>/=10(-12) m) also increased cathepsin K and MMP-9 mRNA levels in mouse and rabbit osteoclasts. Among FGF receptors (FGFR1 to 4) only FGFR1 was detected on isolated mouse osteoclasts, whereas all FGFRs were identified on mouse osteoblasts. FGF-2 (>/=10(-12) m) up-regulated the phosphorylation of cellular proteins, including p42/p44 mitogen-activated protein (MAP) kinase, and increased the kinase activity of immunoprecipitated FGFR1 in mouse osteoclasts. The stimulation of FGF-2 on mouse and rabbit osteoclast functions was abrogated by PD-98059, a specific inhibitor of p42/p44 MAP kinase. These results strongly suggest that FGF-2 acts directly on mature osteoclasts through activation of FGFR1 and p42/p44 MAP kinase, causing the stimulation of bone resorption at physiological or pathological concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896947     DOI: 10.1074/jbc.M910132199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  A common variant in fibroblast growth factor binding protein 1 (FGFBP1) is associated with bone mineral density and influences gene expression in vitro.

Authors:  Nicole Hoppman; John C McLenithan; Daniel J McBride; Haiqing Shen; Jan Bruder; Richard L Bauer; John R Shaffer; Jie Liu; Elizabeth A Streeten; Alan R Shuldiner; Candace M Kammerer; Braxton D Mitchell
Journal:  Bone       Date:  2010-05-05       Impact factor: 4.398

2.  Modulation of unloading-induced bone loss in mice with altered ERK signaling.

Authors:  Jeyantt S Sankaran; Bing Li; Leah Rae Donahue; Stefan Judex
Journal:  Mamm Genome       Date:  2015-11-06       Impact factor: 2.957

3.  Treatment of experimental osteonecrosis of the hip in adult rabbits with a single local injection of recombinant human FGF-2 microspheres.

Authors:  Yutaka Kuroda; Haruhiko Akiyama; Keiichi Kawanabe; Yasuhiko Tabata; Takashi Nakamura
Journal:  J Bone Miner Metab       Date:  2010-03-31       Impact factor: 2.626

4.  Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation.

Authors:  Anne L Jacob; Craig Smith; Juha Partanen; David M Ornitz
Journal:  Dev Biol       Date:  2006-05-27       Impact factor: 3.582

5.  Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.

Authors:  Nan Su; Qidi Sun; Can Li; Xiumin Lu; Huabing Qi; Siyu Chen; Jing Yang; Xiaolan Du; Ling Zhao; Qifen He; Min Jin; Yue Shen; Di Chen; Lin Chen
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

6.  Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats.

Authors:  R A Power; U T Iwaniec; K A Magee; N G Mitova-Caneva; T J Wronski
Journal:  Osteoporos Int       Date:  2004-03-30       Impact factor: 4.507

7.  In vitro and in vivo evidence for stimulation of bone resorption by an EP4 receptor agonist and basic fibroblast growth factor: Implications for their efficacy as bone anabolic agents.

Authors:  M E Downey; L S Holliday; J I Aguirre; T J Wronski
Journal:  Bone       Date:  2008-10-25       Impact factor: 4.398

8.  Estrogen receptor α36 mediates a bone-sparing effect of 17β-estrodiol in postmenopausal women.

Authors:  Hui Xie; Mei Sun; Xiao-Bo Liao; Ling-Qing Yuan; Zhi-Feng Sheng; Ji-Cai Meng; Dan Wang; Zhi-Yong Yu; Lei-Yi Zhang; Hou-De Zhou; Xiang-Hang Luo; Hui Li; Xian-Ping Wu; Qi-You Wei; Si-Yuan Tang; Zhao-Yi Wang; Er-Yuan Liao
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

9.  Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.

Authors:  Carmen Castro-Villegas; Carlos Pérez-Sánchez; Alejandro Escudero; Ileana Filipescu; Miriam Verdu; Patricia Ruiz-Limón; Ma Angeles Aguirre; Yolanda Jiménez-Gomez; Pilar Font; Antonio Rodriguez-Ariza; Juan Ramon Peinado; Eduardo Collantes-Estévez; Rocío González-Conejero; Constantino Martinez; Nuria Barbarroja; Chary López-Pedrera
Journal:  Arthritis Res Ther       Date:  2015-03-09       Impact factor: 5.156

10.  Distribution of inositol 1,4,5-trisphosphate receptors in rat osteoclasts.

Authors:  Kazumasa Morikawa; Tetsuya Goto; Akihiko Tanimura; Shigeru Kobayashi; Kenshi Maki
Journal:  Acta Histochem Cytochem       Date:  2008-04-26       Impact factor: 1.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.